Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Melanotan I (Afamelanotide) is researched primarily for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II. It belongs to the Melanocortin-1 receptor (MC1R) agonist category of compounds.
What Is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation.
The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II. It has attracted significant research interest for its potential effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
How Does Melanotan I Produce These Benefits?
Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synthesis, producing skin darkening without requiring UV exposure.
This multi-pathway activity is why Melanotan I shows potential across several different applications rather than being limited to a single use case.
Can Melanotan I Help With Skin Pigmentation?
Research suggests Melanotan I may support skin pigmentation through its melanocortin-1 receptor (mc1r) agonist activity. Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
Protocols targeting skin pigmentation typically use 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) for 60-day implant cycles; 4-8 weeks injection cycles.
Can Melanotan I Help With Phototoxicity Reduction In Epp Patients?
Research suggests Melanotan I may support phototoxicity reduction in EPP patients through its melanocortin-1 receptor (mc1r) agonist activity. Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
Protocols targeting phototoxicity reduction in EPP patients typically use 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) for 60-day implant cycles; 4-8 weeks injection cycles.
Can Melanotan I Help With Uv-Free Tanning?
Research suggests Melanotan I may support UV-free tanning through its melanocortin-1 receptor (mc1r) agonist activity. Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
Protocols targeting UV-free tanning typically use 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) for 60-day implant cycles; 4-8 weeks injection cycles.
Can Stacking Enhance Melanotan I Benefits?
Used as standalone; not typically combined with other melanocortin peptides.
See our Melanotan I stacking guide for detailed combination protocols.
What Is the Bottom Line on Melanotan I Benefits?
Melanotan I is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. The evidence base includes: Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
- ARA-290 Complete Guide
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.